There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Brickell Biotech (BBI – Research Report), Phio Pharmaceuticals (PHIO – Research Report) and Albireo Pharma (ALBO – Research Report) with bullish sentiments.
Brickell Biotech (BBI)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Brickell Biotech today and set a price target of $4.50. The company’s shares closed last Monday at $3.50, close to its 52-week low of $2.88.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Brickell Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See Insiders’ Hot Stocks on TipRanks >>
Phio Pharmaceuticals (PHIO)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, with a price target of $6.00. The company’s shares closed last Monday at $0.76, close to its 52-week low of $0.62.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Phio Pharmaceuticals with a $6.00 average price target.
Albireo Pharma (ALBO)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Albireo Pharma, with a price target of $54.00. The company’s shares closed last Monday at $24.93.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $63.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BBI:
